San Diego & Redwood City, California, USA, April 6, 2026
Strategic Acquisition Strengthens Rare Disease Leadership
In a major biopharma M&A development, Neurocrine Biosciences has announced a definitive agreement to acquire Soleno Therapeutics in a $2.9 billion all-cash transaction, marking a significant expansion of its endocrinology and rare disease portfolio. The deal, priced at $53.00 per share, reflects a substantial premium and underscores Neurocrine’s strategic focus on high-value, first-in-class therapies. Central to this acquisition is VYKAT™ XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), a rare and life-threatening genetic disorder.
This move not only strengthens Neurocrine’s commercial footprint but also positions the company as a leader in rare disease therapeutics, leveraging Soleno’s innovation and clinical success to drive long-term growth and patient impact.
VYKAT XR Drives Transformational Clinical and Commercial Value
The acquisition is anchored by the strong performance and potential of VYKAT XR, which has already demonstrated rapid market adoption following its FDA approval in 2025. The therapy generated $190 million in revenue in 2025, reflecting significant demand for a treatment addressing hyperphagia, the defining and most debilitating symptom of PWS. This condition leads to chronic hunger, severe behavioral challenges, and increased mortality risks, making VYKAT XR a transformative breakthrough in patient care.
Advertisement
Neurocrine plans to leverage its established commercial infrastructure and expertise in endocrinology to expand the therapy’s reach and maximize its impact. Furthermore, the drug is supported by a strong intellectual property portfolio extending into the mid-2040s, ensuring long-term revenue sustainability and competitive advantage. The integration of VYKAT XR into Neurocrine’s portfolio aligns seamlessly with its strategy of delivering innovative, first-in-class medicines targeting complex disorders at the intersection of neuroscience and endocrinology.
Portfolio Expansion and Long-Term Growth Strategy
With this acquisition, Neurocrine will expand its portfolio to include three high-growth, first-in-class therapies—INGREZZA® (valbenazine), CRENESSITY® (crinecerfont), and VYKAT XR—collectively driving sustained revenue growth through the decade. The transaction enhances Neurocrine’s ability to build a diversified and durable revenue base, while also strengthening its pipeline and innovation capabilities. From a financial perspective, the deal is expected to deliver operational synergies, increased scale, and improved growth trajectory, supported by disciplined capital allocation and integration efficiencies.
The acquisition will be funded through cash reserves and modest debt, reflecting strong financial positioning. Additionally, both companies’ boards have approved the transaction, which is anticipated to close within 90 days, subject to regulatory approvals and customary conditions. This strategic move reinforces Neurocrine’s commitment to accelerating innovation and delivering life-changing therapies to underserved patient populations.
Future Outlook in Rare Disease Innovation
The acquisition of Soleno represents a broader trend in the biopharmaceutical industry toward targeted acquisitions that enhance specialized therapeutic capabilities and address unmet medical needs. Prader-Willi syndrome, affecting approximately 1 in 15,000 individuals, remains a complex condition with limited treatment options, particularly for managing hyperphagia. By integrating Soleno’s expertise and VYKAT XR’s clinical success, Neurocrine is poised to transform the treatment landscape for rare neuroendocrine disorders.
The deal also highlights the growing importance of precision medicine, orphan drug development, and commercial scalability in driving biotech value creation. As Neurocrine continues to expand its footprint, the industry will closely watch how this acquisition influences future innovation, patient access, and competitive dynamics in the rare disease space.
Source: Neurocrine Biosciences, Soleno Therapeutics press release
